期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 23, 期 11, 页码 931-941出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2019.1692816
关键词
Acute lung injury; acute respiratory distress syndrome; cellular communication; extracellular vesicles; microvesicles
资金
- GlaxoSmithKline
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
- Chelsea and Westminster Health Charity
- British Journal of Anaesthesia
- MRC [MR/M018164/1, MR/R001472/1] Funding Source: UKRI
Introduction: Acute respiratory distress syndrome (ARDS) is a heterogeneous and multifactorial disease; it is a common and devastating condition that has a high mortality. Treatment is limited to supportive measures hence novel pharmacological approaches are necessary. We propose a new direction in ARDS research; this means moving away from thinking about individual inflammatory mediators and instead investigating how packaged information is transmitted between cells. Microvesicles (MVs) represent a novel vehicle for inter-cellular communication with an emerging role in ARDS pathophysiology. Areas covered: This review examines current approaches to ARDS and emerging MV research. We describe advances in our understanding of microvesicles and focus on their pro-inflammatory roles in airway and endothelial signaling. We also offer reasons for why MVs are attractive therapeutic targets. Expert opinion: MVs have a key role in ARDS pathophysiology. Preclinical studies must move away from simple models toward more realistic scenarios while clinical studies must embrace patient heterogeneity. Microvesicles have the potential to aid identification of patients who may benefit from particular treatments and act as biomarkers of cellular status and disease progression. Understanding microvesicle cargoes and their cellular interactions will undoubtedly uncover new targets for ARDS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据